186 related articles for article (PubMed ID: 17607300)
21. Viral danger signals control CD1d de novo synthesis and NKT cell activation.
Raftery MJ; Winau F; Giese T; Kaufmann SH; Schaible UE; Schönrich G
Eur J Immunol; 2008 Mar; 38(3):668-79. PubMed ID: 18253929
[TBL] [Abstract][Full Text] [Related]
22. Involvement of secretory and endosomal compartments in presentation of an exogenous self-glycolipid to type II NKT cells.
Roy KC; Maricic I; Khurana A; Smith TR; Halder RC; Kumar V
J Immunol; 2008 Mar; 180(5):2942-50. PubMed ID: 18292516
[TBL] [Abstract][Full Text] [Related]
23. A role for CD1d-restricted NKT cells in injury-associated T cell suppression.
Faunce DE; Gamelli RL; Choudhry MA; Kovacs EJ
J Leukoc Biol; 2003 Jun; 73(6):747-55. PubMed ID: 12773507
[TBL] [Abstract][Full Text] [Related]
24. Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer.
Kita H; Naidenko OV; Kronenberg M; Ansari AA; Rogers P; He XS; Koning F; Mikayama T; Van De Water J; Coppel RL; Kaplan M; Gershwin ME
Gastroenterology; 2002 Oct; 123(4):1031-43. PubMed ID: 12360465
[TBL] [Abstract][Full Text] [Related]
25. Glycosylphosphatidylinositol-anchored mucin-like glycoproteins from Trypanosoma cruzi bind to CD1d but do not elicit dominant innate or adaptive immune responses via the CD1d/NKT cell pathway.
Procópio DO; Almeida IC; Torrecilhas AC; Cardoso JE; Teyton L; Travassos LR; Bendelac A; Gazzinelli RT
J Immunol; 2002 Oct; 169(7):3926-33. PubMed ID: 12244192
[TBL] [Abstract][Full Text] [Related]
26. A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance.
Terabe M; Swann J; Ambrosino E; Sinha P; Takaku S; Hayakawa Y; Godfrey DI; Ostrand-Rosenberg S; Smyth MJ; Berzofsky JA
J Exp Med; 2005 Dec; 202(12):1627-33. PubMed ID: 16365146
[TBL] [Abstract][Full Text] [Related]
27. CD1d-restricted NKT cells: an interstrain comparison.
Hammond KJ; Pellicci DG; Poulton LD; Naidenko OV; Scalzo AA; Baxter AG; Godfrey DI
J Immunol; 2001 Aug; 167(3):1164-73. PubMed ID: 11466330
[TBL] [Abstract][Full Text] [Related]
28. Deficiency of invariant V alpha 14 natural killer T cells decreases atherosclerosis in LDL receptor null mice.
Rogers L; Burchat S; Gage J; Hasu M; Thabet M; Willcox L; Ramsamy TA; Whitman SC
Cardiovasc Res; 2008 Apr; 78(1):167-74. PubMed ID: 18192239
[TBL] [Abstract][Full Text] [Related]
29. ILDR2: an endoplasmic reticulum resident molecule mediating hepatic lipid homeostasis.
Watanabe K; Watson E; Cremona ML; Millings EJ; Lefkowitch JH; Fischer SG; LeDuc CA; Leibel RL
PLoS One; 2013; 8(6):e67234. PubMed ID: 23826244
[TBL] [Abstract][Full Text] [Related]
30. Microsomal triglyceride transfer protein lipidation and control of CD1d on antigen-presenting cells.
Dougan SK; Salas A; Rava P; Agyemang A; Kaser A; Morrison J; Khurana A; Kronenberg M; Johnson C; Exley M; Hussain MM; Blumberg RS
J Exp Med; 2005 Aug; 202(4):529-39. PubMed ID: 16087713
[TBL] [Abstract][Full Text] [Related]
31. Activating immunity in the liver. I. Liver dendritic cells (but not hepatocytes) are potent activators of IFN-gamma release by liver NKT cells.
Trobonjaca Z; Leithäuser F; Möller P; Schirmbeck R; Reimann J
J Immunol; 2001 Aug; 167(3):1413-22. PubMed ID: 11466360
[TBL] [Abstract][Full Text] [Related]
32. Ex vivo analysis of resident hepatic pro-inflammatory CD1d-reactive T cells and hepatocyte surface CD1d expression in hepatitis C.
Yanagisawa K; Yue S; van der Vliet HJ; Wang R; Alatrakchi N; Golden-Mason L; Schuppan D; Koziel MJ; Rosen HR; Exley MA
J Viral Hepat; 2013 Aug; 20(8):556-65. PubMed ID: 23808994
[TBL] [Abstract][Full Text] [Related]
33. CD1d expression by hepatocytes is a main restriction element for intrahepatic T-cell recognition.
Agrati C; Martini F; Nisii C; Oliva A; D'Offizi G; Narciso P; Nardacci R; Piacentini M; Dieli F; Pucillo LP; Poccia F
J Biol Regul Homeost Agents; 2005; 19(1-2):41-8. PubMed ID: 16178273
[TBL] [Abstract][Full Text] [Related]
34. Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection.
Baron JL; Gardiner L; Nishimura S; Shinkai K; Locksley R; Ganem D
Immunity; 2002 Apr; 16(4):583-94. PubMed ID: 11970881
[TBL] [Abstract][Full Text] [Related]
35. The CD1d-binding glycolipid alpha-galactosylceramide enhances humoral immunity to T-dependent and T-independent antigen in a CD1d-dependent manner.
Lang GA; Exley MA; Lang ML
Immunology; 2006 Sep; 119(1):116-25. PubMed ID: 16792697
[TBL] [Abstract][Full Text] [Related]
36. Direct regulatory role of NKT cells in allogeneic graft survival is dependent on the quantitative strength of antigenicity.
Oh K; Kim S; Park SH; Gu H; Roopenian D; Chung DH; Kim YS; Lee DS
J Immunol; 2005 Feb; 174(4):2030-6. PubMed ID: 15699132
[TBL] [Abstract][Full Text] [Related]
37. Dietary fatty acids modulate antigen presentation to hepatic NKT cells in nonalcoholic fatty liver disease.
Hua J; Ma X; Webb T; Potter JJ; Oelke M; Li Z
J Lipid Res; 2010 Jul; 51(7):1696-703. PubMed ID: 20185414
[TBL] [Abstract][Full Text] [Related]
38. CD1-restricted T cells and tumor immunity.
Swann JB; Coquet JM; Smyth MJ; Godfrey DI
Curr Top Microbiol Immunol; 2007; 314():293-323. PubMed ID: 17593666
[TBL] [Abstract][Full Text] [Related]
39. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells.
Metelitsa LS; Naidenko OV; Kant A; Wu HW; Loza MJ; Perussia B; Kronenberg M; Seeger RC
J Immunol; 2001 Sep; 167(6):3114-22. PubMed ID: 11544296
[TBL] [Abstract][Full Text] [Related]
40. Activation of hepatic NKT cells and subsequent liver injury following administration of alpha-galactosylceramide.
Osman Y; Kawamura T; Naito T; Takeda K; Van Kaer L; Okumura K; Abo T
Eur J Immunol; 2000 Jul; 30(7):1919-28. PubMed ID: 10940881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
